Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.It is the largest pharmaceutical company in India.
What Sun files
- Others66
- Updates46
- Investor Meet43
- Important26
- Dividend/Bonus8
- PPTs7
Here's a concise, retail-friendly summary of Sun Pharma's investor presentation: **1. Business Performance:** Sun Pharma posted strong FY26 sales of Rs 58,220.1 Cr, up 11.9% YoY. India Formulations (33% of sales) remained India's largest pharma business. US Formulations contributed 29%, with Innovative Medicines (22% of total sales) growing to USD...
Sun Pharma is set to transform into a global pharma leader. The company recently announced the acquisition of Organon & Co. **Business Performance:** Sun Pharma's FY25 revenue was $6.2 billion. This acquisition is projected to nearly double combined revenue to ~$12.4 billion and EBITDA to ~$3.7 billion. The merged entity...
Sun Pharma delivered strong Q3 FY26 results with gross sales up 15.1% year-on-year to Rs 15,469.1 Cr. Nine-month gross sales rose 11.3% to Rs 43,660.4 Cr. India Formulations led growth, up 16.2%, followed by Emerging Markets at 28.3%, and US Formulations at 6.2%. Adjusted Net Profit for Q3 increased 9.9%...
Sun Pharma reported H1 FY26 Gross Sales of **Rs 28,191.3 Cr**, up 9.3% YoY. Adjusted Net Profit for the half-year stood at **Rs 6,114.1 Cr**, a 4.1% YoY increase, with an Adjusted EPS of **Rs 25.5**. Q2 FY26 EBITDA margin was strong at 31.3%. India formulations grew 12.4% in H1,...
Sun Pharma delivered strong FY25 results with sales of Rs 52,041 Cr, up 9% year-on-year. Adjusted net profit surged 19% to Rs 11,984 Cr. Q1 FY26 gross sales rose 10.1% YoY to Rs 13,786 Cr. India formulations (33% of sales, #1 pharma company) and US formulations (31% of sales, #12...